Eris Lifesciences - 100% of sales from India Pharma Market

Stock Opportunities
110

Descent set of Q3 results. Most of the growth attributable to the acquired portfolios in the last 1 yr. PAT is flat despite steep rise in Consolidated Revenues due to higher depreciation, amortisation and employee expenses that come with acquisitions.

Key positive - Acquisition of Derma portfolio of Glennmark Pharma for 340 cr. The portfolio’s last yr sales were at 87 cr. Combined with Oaknet’s ( a Derma Formulations company ) acquisition last yr, Eris is now becoming a serious branded derma player in India. Should be a long term positive.

Disc : holding a tracking position. Biased.

3 Likes
111

Company came up with mixed set of results (27% sales growth, flat PAT YOY). Organic growth lagged due to loss in sale of 2 molecules, one due to legal issue and other was a covid product. Oaknet has turned out to be a very good acquisition, and this has given them the confidence to acquire 9 derma brands from Glenmark. Concall notes below.

FY23Q3

  • Guidance lowered to 25-26% (from 30% earlier) and 14-15% EBITDA growth (lowered from 16-17%) for FY23.
  • Zayo revenues was 30 cr. in FY22 which has gone to zero due to legal issue. One more product launched during the 2nd COVID wave (called Zandi) was discontinued (30 cr. revenue contribution in FY22) and there was sales return of 18-20 cr. in 9MFY23
  • Acquired 9 medical dermatology brand (anti-fungal & anti-psoriasis) from Glenmark. 3 brands (Onabet, Halovate and Sorvate) are ranked #1 in their respective segments. 3 other brands (Demelan, Dosetil and Aceret) are ranked in top-3 of their respective segments. These brands have declined for Glenmark in past few years, they were considered as non-core by Glenmark
  • FY22 revenue base of these 9 brands: 85 cr. (purchased at 340 cr.). Will be financed fully through borrowings (8% rates). Gross margins are 78%+
  • Net debt / EBITDA will go to 0.8-0.9x after current acquisition
  • 70% of dermatology sales come from medical dermatology and is growing at 9-10%. Eris wants to position themselves strongly there
  • Oaknet: 60 cr. at 27% EBITDA margins. 9MFY23: 183 cr. (160 cr. has accrued to Eris) at 24% margins. Will exceed 50 cr. EBITDA in FY23.
  • Oaknet had 60% growth in doctor prescription (July, August audit)
  • Insulin sales will be around 20 cr. in FY23 (was 6 cr. in Q3; expect 7-8 cr. in Q4). Will burn (-20 cr.) of EBITDA on Insulin. EBITDA burn has come down to (-4 cr.) this quarter. Expect next year to reach 50 cr. in revenues with breakeven EBITDA
  • Margins have bottomed out in FY23 and will increase in FY24
  • Zomelis reaches 92 cr. MAT in Dec 2022 (#1 rank), Gluxit reaches 51 cr. MAT in Dec 2022 (#2 rank)
  • MRs: 3000 (consolidated), 2225 (standalone)
  • Tax rate: 9-10% for FY23 and FY24. For FY25, blended booked tax rate will be 27-28%. Cash tax rate will continue to be 17% for next 5-years and booked tax rate will also come to 17-18% over 5-years post FY25
  • Trial batches have started in Gujarat. Capex is largely finished. Depreciation will be 9-10 cr. per year
  • On 75 cr. of gross block in Guwahati, Eris does turnover of 800 cr (10x fixed asset turns). So with Gujarat facility coming on stream, there will be no requirement of further manufacturing facilities for a long time to come

Disclosure: Invested (position size here, bought shares in last-30 days)

5 Likes
112

Eris Lifesciences Q3 concall highlights -

Acquired 09 Dermatology brands from Glennmark Pharma

Had acquired Oaket Pharma ( a Derma company ) in May 22

Latest acquisition helps them consolidate their position in Derma Mkt, specially in anti fungal and anti psoriasis mkt

03 of Glenmark’s acquired brands are No1 in their respective segment. 03 others are among top 03

These 09 brands have a revenue base of 85 cr, Acquired for 340 cr, funded via borrowings @ 8pc

Post deal derma contribution for Eris will rise to 13 pc from 07 pc currently

Derma mkt rank to improve to No 6 from No 12 Oaknet’s

Q3 revenues at 60 cr, EBITDA at 27 pc up from 10 pc, pre acquisition

Oakent to clock yearly EBITDA > 50 cr, 1 yr ahead of expectations

Cardio-Metabolic share of revenues for Eris at 54 pc, grew by 15 pc

Eris’s biggest anti-diabetic brands are Zomelis and Gluxit

Derma+CNS+Women’s health - The emerging portfolio for Eris has grown by 15 pc. All three combined form 25 pc of Eris’s revenues

VMN (Vit-Minerals-Neutraceuticals) account for 17 pc of Eris’s revenues. Grew by 19 pc

Added 200 Medical Reps in FY 23

Launched various new and innovative products specially in Cardio-Metabolic space

These led to some compression in Gross Margins

Consolidated sales at 424 cr, up 27 pc

EBITDA at 132 cr, up 12 pc

PAT at 100 cr @ 24 pc net margins!!!

Consolidated EBITDA margins at 32 pc despite Oaknet integration, commissioning of new mfg plant in Gujarat and various new brand launch related investments

Margins to improve next FY onwards

All this growth despite base Qtr having an aprox sale of 10 cr of Covid drugs

Started selling ( new launch ) Insulin this yr. Aim to hit 22-24 cr sales this yr, 50 cr next yr

Currently having aprox 3000MRs. Oaknet may add a few more next yr

Next yr onwards, EBITDA growth to be better than top line growth as most investments are behind

Aim to launch Glargine by Q3 - Q4 next yr

Current consolidated yield of MRs at Rs 5lakh/month

May go for more inorganic opportunities next year as well

No of products going off patent and are likely to be launched next yr in India are quite high in the diabetes space

Disc : holding, biased

4 Likes
113

Eris’s 7 % revenue is coming from the products which are now come under NLEM policy of government of India. The margin in these products will be declined by 15- 20 %. So overall margin of company may declined 1-3 % in coming quarters. I’m not yet invested but waiting for some price correction to enter.

114

Eris does another acquisition in derma space, this time valuations paid were quite high (5.5x sales). Call notes below.

16.03.2023

  • Acquired 9 cosmetic dermatology brands from Dr. Reddy for 275 cr. (50 cr. primary sales; 5.5x sales; 78-80% gross margins). Higher valuation was paid because growth is higher in cosmetology (15-20%)
  • Will be financed through borrowings (8-8.5% variable rate loan). 6 brands in top-5 with 3 brands in top-3. 3 brands have 10 cr.+ annual sales
  • Debt will be 850 cr. in FY23, net debt to EBITDA will be 1-1.5x in FY23
  • Used string of pearls strategy to build dermatology portfolio targeting portfolio gaps. Now time is to consolidate
  • Adding 40-50 MRs to dermatology field force to promote cosmetic dermatology (existing field force is 640 in Oaknet). Cosmetic dermatology is growing faster than medical dermatology
  • Eris will rank #3 (7% market share) in covered market in dermatology (Eris now covers 45% of dermatology market), have spent 1265 cr. in building dermatology portfolio. Aggregated revenue is expected to exceed 400 cr. in FY24
  • FY24 guidance for Oaknet: 400 cr. revenues at 36-38% EBITDA margins; 5 lakh PCPM
  • Contribution from emerging therapies (dermatology + CNS + women’s health) has increased to 28% (from 12%)
  • Third party manufacturing is 15-20% for the entire company

Disclosure: Invested (position size here, no transactions in last-30 days)

6 Likes
115

The question that comes to mind is why glenmark and drl selling despite being in leadership positions in the segment.
Low base
Low growth
Separate mr team

Are possible reasons that come to my mind, leading to a lower ROE.

116

04.05.2023 India Ratings notes

  • AA- rating (same as CRISIL)
  • 2,000 stockists, 3,669 field force (2,555 medical representatives and 1,144 field managers) and over 5,00,000 chemists
  • Top 15 mother brands contribute 75% to revenue
  • Majority revenues come from metros and class I cities
  • Ind-Ra expects them to grow at a CAGR of around 21% from FY22-FY26(estimate)
  • Utilized 41% of fund-based limits over 12 months ended March 2023

Disclosure: Invested (position size here, no transactions in last-30 days)

3 Likes
117

Muted set of nos continues for Eris, with organic growth at 9.5%. However, their big brands such as Glimisave, Eritel, etc. have finally started growing after a gap of 2-3 years. Management is very confident of recouping margins in FY24 and is looking to pay down 400 cr. of debt in FY24.

image
image1920×557 95.9 KB

FY23Q4

  • Organic revenue growth was only 9.5% due to discontinuation of Zac-D (covid product) and Zayo (legal issues). Ex of these, growth was 15.6% in FY23
  • Spent 1265 cr. in dermatology acquisitions
  • Clocked 17 cr. revenues in Insulin, should be EBITDA neutral in FY24. Q4 run rate was a bit lower due to supply issues
  • Trade generics: Hoping to not incur loss in FY24, not focusing on growth in this segment
  • Will give FY24 guidance at end of Q1 with more visibility on integration of Glenmark and Dr. Reddy brands
  • Dermatology brands are currently outsourced, looking to bring in to Gujarat facility by end of FY24 (15% tax rate)
  • FY24 ETR: 14-15%
  • Intend to pay down 400-500 cr. debt in FY24
  • Eris standalone metrics: 82% gross margins, 5L YPM and 38% EBITDA. Oaknet metrics: 78-80% gross margins, 5L YPM
  • MR expansion: will setup 1 more division in dermatology in H2FY24 (~100 people)
  • MR: 2200 (standalone) + 700 (Oaknet)
  • Oaknet FY23 revenues (pro-forma): 250 cr. (booked 226 cr. for 10.5 months) and 61 cr. EBITDA

Disclosure: Invested (position size here, no transactions in last-30 days)

2 Likes
118

Is there cyclicality in this business? Usually, Q4 is lower than Q3.

1 Like
119

Eris Lifesciences Q4 highlights -

Revenues at 403 vs 306 cr

EBITDA at 119 vs 97 cr

EBITDA margins at 30 vs 32 pc

PAT at 61 vs 80 cr (due higher interest outgo, higher amortisation, lower other income - all due aggressive inorganic acquisitions made by the company in FY 23)

Consolidated revenue growth for Q4 and FY 23 at 32 and 25 pc

Standalone ( organic business ) revenue growth for Q4 and FY 23 at 11.5 and 9.5 pc

Consol Debt at 774 cr. Expect accelerated pre-payments in FY 24 due generous cash flow generation

Oakent business ( Derma focussed company, acquired early LY) -

Revenues at 250 vs 195 cr, up 23 pc ( for full FY )

Generated EBITDA of 61 vs 20 cr YoY

Added complementary brands to this business by acquiring medical and cosmetological brands of Glenmark, DRL in FY 23

Oaknet’s MR productivity increased from 2.3 to 3.2 lakh / month. EBITDA expanded from 10 to 24 pc

Basically - a very sucessful turnaround of Oakent under Eris

Eris Life - therapy wise revenue share -

Diabetic- 29 pc
Cardiovascular- 21 pc
Vit & Minerals- 16 pc
Derma- 14 pc

CNS- 7 pc
Women Health- 5 pc
Others- 9 pc

Revenue wise Brand strength -

4 brands > 100 cr revenues
6 brands > 70 cr revenues
5 brands > 50 cr revenues

Added 200+ MRs in FY 23

Total cost of acquisition of Oaknet +Derma brands of DRL and Glennmark at 1265 cr incurred in FY 23

Consolidated gross margins sustaining at 80 pc !!

With Oaknet scale up and higher sales of Injectable Insulins, expect improvement in Gross, EBITDA margins in FY 24!!

Eris MJ (JV) for oral insulin hit 17 cr revenues for FY 23. Could have been higher but for supply issues in Q4

Going to launch a number of new formulations in FY 24. Even after accounting for these launches, expect significant jump in EBITDA margins in FY 24

Currently all Derma formulations being made by third parties. Intend to bring them in-house in their new Gujarat facility

Top 20 brands account for 70 pc of revenues

Effective tax rate should be around 14-15 pc this yr

Intend to pay back 400-500 cr of Debt this yr

Business Matrix improvements should be visible from Q1 FY 24 onwards

Going to add aprox 100 MRs in H2 FY 24 in Oaknet division

Disc: holding a tracking position, biased

Once the topline growth starts translating into bottomline growth, I personally expect a significant re-rating in the stock price … something similar to JB Chemicals

That a hunch

Do ur own homework before investing

3 Likes
120

Cycle is more granular … like monsoons come with illnesses … and winter comes with its own ailments …

121

Companies do sell brands and there are ready people who want to buy

122

Company reported very good revival in margins, sales growth was largely driven by inorganic acquisition with sales growing by 17%, EBITDA by 32% but EPS being flat. Tax rates have started hitting them as Guwahati tax shelter is over now, Gujarat ramp up can again bring down tax rates. More interestingly, Eris is launching a lot of products in FY24 again. They are also spending R&D and transitioning from a largely marketing focused co. Concall notes below.

FY24Q1

  • FY24 organic growth: Expect IPM to grow at 8% and Eris to grow at 12%. Have seen volume decline in Q1 and most growth is coming from price increase and new product launches. Very confident of double digit growth in remainder of year
  • R&D: Spending 30 cr. on 10 combination molecules (3 cr./molecule). Transitioning from a pure marketing organization to doing R&D themselves
  • 2 FDCs in oral diabetes in clinical trials and will be launched in Q3FY24
  • 2 FDCs in cardiology in clinical trials and will be launched in Q4FY24
  • These 4 FDCs will be new mother brands
  • 6 FDCs are under development (2 diabetes, 2 CNS, 2 Gastro)
  • Relaunced Zayo in January 2023 and has achieved monthly run rate of 2 cr. in June 2023
  • Linagliptin will be launched at patent expiry (August 2023)
  • Insulin sales ramped up to 9 cr. in Q1FY24 with (-2.5 cr.) EBITDA loss (guidance: 50 cr. sales in FY24 and EBITDA breakeven by Q4FY24)
  • MJ’s Glargine and Liraglutide completed Phase III trials and is slated for commercial launch in Q4FY24
  • Gujarat: capex of 230 cr.+ (vs earlier guidance of 170-180 cr.). Capacity utilization was 14% in June 2023 and will ramp up in FY24.
  • Commercialization of Derma block will deliver margin benefits starting Q4FY24
  • Oaknet EBITDA margins are now 35%
  • Dermatology: First-in-market product like Minoxidil Booster and Hydroheal Nova launched in Q1, pipeline of 8-10 products to be launched in FY24. Entering Pediatric Dermatology in Q2FY24
  • Of acquired derma brands from Dr Reddy and Glenmark, have lost 25% of sales in Q1 and hope to get to 100% run rate by Q2FY24
  • PCPM: 5.02 lakh
  • Net debt reduced by 102 cr. (to 672 cr.)
  • Quarterly depreciation will be ~41 cr.

Disclosure: Invested (position size here, no transactions in last-30 days)

7 Likes
123

Eris life Q1 concall highlights -

Successfully integrated Oaknet into Eris’s mainstream business

Capacity utilisation ramp up happening at second formulations facility in Gujarat (at 14 pc utilisation now)- started in Mar 24

Derma block expansion underway in the a/m facility

8-10 launches lined up for remainder of FY 24. Entering paediatric dermatology in Q2

Have a pipeline of 10 new FDFs in diabetic, GI, neurological space-these will be first in the Mkt combos. To be launched in FY 24/25

Derma insourcing wef Q4 FY 24 to further improve margins

Injectable diabetic revenue tgt for FY 24 at 50 cr. To launch Glargine and Liraglutide by Q4. Aim to achieve EBITDA breakeven here by Q4 FY24

Q1 Fin outcomes -

Revenues - 467 vs 398 cr, up 17 pc
EBITDA - 169 vs 129 cr, up 31 pc ( margins up 400 bps )
PAT - 94 vs 93 cr

PAT hit by higher amortisation and interest costs, lower treasury income

Reduced debt by 102 cr in Q1 to 672 from 774cr on 31 Mar 24

Current brand strength -

4 brands with > 100 cr revenues
6 brands with > 70 cr revenues
5 brands with > 50 cr revenues

Added 200 MRs in FY 23

Oaknet’s EBITDA margin at 35 pc vs 24 pc LY vs 10 pc at the time of acquisition

Diabetes injectable revenues were at 17 cr in FY 23 with EBITDA loss of 20 cr. Expect to hit 50 cr sales in FY 24 with EBITDA break even

Depreciation+Amortisation to continue at 40 cr/qtr this FY

Aim to reduce debt below 400 cr by end FY24

Aim to have EBITDA margin of 35 pc for FY24. Moderation to happen in H2 vs H1 due marketing spends on new launches

Organic portfolio (excluding Oaknet + brands acquired from Dr Reddy and Glennmark) grew 400 bps higher than the IPM

The 10 new brands (new FDF combos) to be launched in next 12-18 months to contribute min 8-10 cr in revenues each after first yr of launch. Thereafter, it depends on the product’s strength and mkt conditions

Confident of even better organic growth for the remaining part of FY

No capex (except maint) planned this yr

Yield per MR at Rs 5 lakh/month

PAT growth to accelerate next yr due to even higher topline and reduced debt

Not looking for fresh acquisitions in near future

Company believes, it should clock 700-720 cr EBITDA this yr vs 540 cr LY

Most of the cash generated to go into debt reduction

Topline expected to hit 2000-2100 cr this yr

Q1 has been weak for the IPM for last 2-3 yrs in a row. Growth generally picks up post Q1. Hoping for the same this yr too

Q2 is the best Qtr for derma mkt due fungal infections

Disc: holding from 630 levels

IMHO : being a pure play branded India formulations player, it should command better valuations. But - that’s only an opinion

5 Likes
124
1 Like
125

AR23 notes

Diabetes

  • Insulin:
    o Commercialized 2 products: Human Insulin (Xsulin – Regular and premix as vials and cartridges), Glargine (Xglar)
    o Pipeline consists of Liraglutide and other insulin analogs
    o Clocked 17 cr. revenue with operating losses of (-20 cr.)
    o Expect losses to narrow in FY24 and business to be profitable in FY25
    o Promoted through 200-member field team
  • Glimisave crossed 300 cr. and Zomelis crossed 100 cr.
  • Full-service presence across all the oral segments – Sulphonylureas, DPP4 Inhibitors (vildagliptin, sitagliptin) and SGLT 2 Inhibitors (dapagliflozin) – and in injectable Anti-Diabetes therapies
  • DPP4 and SGLT2 portfolio have grown at a 50% CAGR over last 3 years
  • New launches: Glura (DPP4 Inhibitor), Sidacor
  • In covered market of ~14,000 cr., ranks #8 in terms of revenue and #5 as per Rx

image
image1883×604 105 KB

Cardiac

  • Eritel grew at 19% and is now 175+ crore mother brand
  • New launches: Zayo (relaunched), Bisopharm, Cardexa
  • Number of major molecules will lose exclusivity in cardio metabolic segment in next 3-5 years

image
image1894×566 103 KB

Dermatology

  • Spent 1265 cr. spent in 3 acquisitions
  • Acquired Oaknet Healthcare for 650 cr.
  • Acquired 9 Derma Brands from Glenmark (Medical dermatology) for 340 cr.
  • Acquired 9 Derma Brands from Dr. Reddy (Cosmetic Dermatology) for 275 cr.
  • Acquisition with an “owner manager” mindset, with willingness to do the hard work to create value
  • Oaknet clocked 22% organic growth in FY23 after 3 flat years during FY20-FY22. EBITDA margin expanded from 10% in FY22 to 24% in FY23 and will expand further in FY24
  • Ranks #3 in its Dermatology covered marked with a share of 7%
    image
    image787×468 40.2 KB

Vitamins, minerals and nutrients

Women’s health

  • New launches: Drolute (Dydrogesterone), FCM injection

image
image1915×557 76 KB

Central nervous system

Capex and manufacturing

  • New manufacturing plant in Gujarat began commercial operations in March 2023 and augments capabilities in oral solids, oral liquids, sterile injectables and creams/ ointments. Its built by WHO GMP standards and has 10x footprint of Guwahati site
  • Manufacturing facility at Guwahati contributed 70% of products sold (by value) vs 80% in FY22
  • Capex: 208 cr. (vs 53 cr. in FY22). Taken from gross block increase

General

  • Top-20 mother brands account for 70% of revenue and clocked 17% growth in FY23
  • 15 brands ranked among top-5 in their therapies
  • 4 mother brands with revenues of 100+ cr., 6 mother brands with revenues of 70-80 cr. and 5 mother brands with revenues of 50-60 cr.
  • Excluding impact of Covid products and “at risk” launches, standalone revenue grew by 15.6%
  • Consolidated revenue grew at 25% and 31% excluding impact of covid products and “at risk” launches
  • Preservation of consolidated gross margin of ~ 80% is an integral component of growth strategy
  • Introduced a reward program to recognize top performers from various departments (sales, marketing, manufacturing, etc.)
  • YPM (Yield per Man per Month) in standalone operations (branded formulations business) for FY23 stood at INR 5 lakh per month
  • Future growth: In-licensing, exploring newer therapeutic areas and future patent expiries
  • Permanent employees: 3’548 (median increase was 8.68%)
  • Share price: 550.9 (low), 749.85 (high)
  • Shareholders: 46’403
  • Expected credit loss provided for: 3.5 cr. (vs 3.5 cr. in FY22)
  • Amit Bakshi increased shareholding from 40.28% in FY22 to 40.84% in FY23
  • Contingent liability: 28 cr. (vs 24.5 cr. in FY22)
  • Auditor remuneration: 1.28 cr. (vs 0.5 cr. in FY22)
  • Bankers: Axis, HDFC, SBI, Citi

Industry trends

  • With ~55% share in IPM, chronic and sub-chronic therapies grew by 10.6% in FY23, while acute therapy comprising ~45% of IPM, grew by 7.8%
  • For Eris, chronic and sub-chronic contributes 87% (vs 55% for IPM)
  • NLEM: 7% for Eris (vs 14% for IPM)

Patient initiatives

  • Ambulatory Blood Pressure Measurement on Call: 9,000 clinicians have used this service and over 130,000 patients have been screened through ABPM on Call
  • 24 hours Ambulatory Electrocardiogram: 68,000+ patients have been screened
  • Continuous Glucose Monitoring (CGM): 48,000+ patients have been screened
  • Sleep Study on call: 24,000+ patients have been screened
  • Montana ANC Associate (detect Hb, PIH and GDM in Fetal Origin of Adult Disease): 200,000+ patients have been screened

Disclosure: Invested (position size here, no transactions in last-30 days)

8 Likes
126

Margin revival continues for Eris. As they turnaround acquisitions, their appetite for newer acquistions keep increasing, with them now acquiring nephrology and dermatology brands from Biocon at 3.7x EV/sales. They are confident of increasing margins of acquired portfolio from 20% to 30% in a years’ time. Concall notes below.

FY24Q2

  • FY24 guidance: 2000-2100 cr. sales, 700-710 cr. EBITDA (30% growth), 410-415 cr. PAT (without Biocon acquisition)
  • Capital allocation strategy: focus on using operating cashflows to expand into newer therapies through acquisitions (Strides gave them Nephrology, Oaknet gave them Dermatology, Biocon adds to Nephrology and Dermatology)
  • Acquired 12 brands in Nephrology (Organ transplant focused power brands like Tacrograf and Renodapt; 65 cr. sales; 40 MRs) and 9 brands in Medical dermatology (Psoriasis and Atopic Dermatitis; 35 cr. sales; 50 MRs; Psorid is 25 cr. brand) from Biocon for 366 cr. (including working capital; 3.7x sales; 280 cr. will be from debt). Total personnel: 90 MRs + 30 others. Very high MR productivity (9 lakhs YPM). Will reach 30% EBITDA margin in FY25 from 20-22% currently
  • Amortization will be 17-18 cr. annual amortization (20 year window)
  • Psoriasis market is 1100 cr. (2-year growth of 20%). This acquisition makes them second largest in psoriasis with 11% market share
  • Nephrology market is 3000 cr. growing at 11%
  • When there is personnel acquisition (and not only brand acquisition), then leakage of sales is lower
  • In Glenmark acquisition, have reached 100% of sales but for Dr Reddy have only managed to get to 90-92% by Q2
  • Organic growth: 7-8% (vs covered market growth of 2.5% in H1)
  • Launches
    o 2 FDCs in oral diabetes approved (Gliclazide-Dapagliflozin, Gliclazide-Sitagliptin) and will be launched this quarter. Both are first to market
    o Launched 2 “at-risk” products (Linares & FCM) in Q2
    o Launched 4 products in dermatology in Q2 (Hydroheal, Nova, Efatop Hydra, Crisanew)
    o Pipeline increased to 14 from 10 in Q1: Added 2 FDCs in gynecology, 1 first time to Indian launch in cardiovascular and 1 in respiratory therapy in FY25
  • Their 50 cr.+ brands reduced from 15 in Q1 to 13 in Q2. 100 cr.+ brands increased from 4 in Q1 to 5 in Q2
  • Will start commercial production in dermatology in Q4FY24
  • Insulin: 10 cr. sales in Q2FY24; (-1.8 cr.) EBITDA loss
  • Market coverage: 83% in diabetes, 54% in cardiovascular, 50% in dermatology

Disclosure: Invested (position size here, no transactions in last-30 days)

10 Likes
127

Hello VP , Harsh and friends

Any thoughts on recent acquisition by Eris Lifesciences

It seems to have acquired assets in nephrology and derma sciences from Biocon. Looks promising . will update with more info. maybe members from medical fraternity can opine …
Malolan

1 Like
129

Interesting…besides the 51 % by Eris, the promoters are buying another 19 % in their personal capacity in Swiss Parenterals.

image
image950×429 69.1 KB

4 Likes
130

Eris Lifesciences -

Q3 FY 24 concall highlights -

Current rank in IPM @ 21st vs 29th in Mar 18

Make share in Diabetes @ 5 pc, in Vit/Minerals @ 2.5 pc

Last 6 yrs avg GMs > 80 pc, EBITDA margins > 35 pc

Therapy wise sales breakdown -

Diabetes - 28 pc

Cardio - 19 pc

Vit/Min - 16 pc

Derma - 14 pc

CNS - 6 pc

Women’s health -5 pc

Nephro - 3 pc

Others - 8 pc

Q3 financial outcomes -

Sales - 486 vs 423 cr

EBITDA - 176 vs 137 cr ( margins @ 36 vs 32 pc )

PAT - 116 vs 107 cr ( due higher amortisation, interest costs )

Vision 2029 - to hit a annual revenue run rate of Rs 5000 cr / yr

Acquired SWISS PARENTERALS in Q3. Its a dossier driven - generic and speciality Injectables business focussed on RoW Mkts ( Africa, LATAM, ME, Asia Pacific ). They own 02 manufacturing plants in Gujarat. Swiss Parenterals currently does a topline of 250 cr with 25 pc PAT margins. Eris has bought 51 pc stake for 637 cr in the company. An additional 19 pc stake shall be acquired separately by Eris promoter group for 237 cr

It also offers Eris an ideal platform to launch India focussed Sterile - Injectables portfolio

Company’s 100 cr/yr brands -

GlimiSave ( anti-diabetic ) - 300 cr

Eritel ( Telmisartan - anti-hypertensive ) - 170 cr

ReNerve ( Gabapentin + Methylcobalamin - CNS drug ) - 160 cr

Zomelis ( anti-diabetic ) - 105 cr

Company’s 50 cr/yr brands -

Tayo ( Calcium + Vit D supplement ) - 80 cr

Gluxit ( anti- diabetic ) - 75 cr

Remylin ( folic acid supplement ) - 70 cr

Company plans to launch Glargine and Liraglutide in Q4 ( both are biosimilars )

The Derma companies and brands acquired by the company in FY 22 have seen an EBITDA margin improvement from 10 pc to 35 pc inside 2 yrs !!!

Both the injectable plants acquired by Eris are currently running on single shift basis offering significant operating leverage opportunity to the company

Eris intends to do a business of 100 cr in the domestic mkts from year-1 iro the newly acquired Injectable facilities

Looking at Swiss Parenteral’s RoW focus ( basically branded and unregulated mkts ), wide product portfolio ( they make a lot of injectable antibiotics ) , R&D focus and juicy EBITDA margins - its a sweet sweet deal for Eris

Swiss Parenteral currently operates on distributors led front end in the RoW mkts. After partnership with Eris and Eris’s brand name, the front end distribution challenge in the Indian Mkt is virtually gone for Swiss. Hence, its a win win for both

Eris had acquired the derma and nephro brands of Biocon Biologics for 366 cr in Mid Nov 23. This business is doing a Gross Margins of around 70 pc vs 50 pc at the time of acquisition !!! This portfolio is likely to do a revenue of 10 cr or so / month from next FY onwards

Eris intends to put up another Injectables plant under the guidance of Swiss Parenteral. It may need a capex of 40-60 cr

Company is on track to achieve 2000 cr topline, 700 cr EBITDA, 400 cr PAT for FY 24

Disc: holding, a core holding, biased, added more recently, not SEBI registered

7 Likes